Selected article for: "acute respiratory and lopinavir hydroxychloroquine"
Author: Martinez, Miguel Angel
Title: Clinical Trials of Repurposed Antivirals for SARS-CoV-2
  • Cord-id: 5q5mele8
  • Document date: 2020_8_20
    • ID: 5q5mele8
    Snippet: The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has prompted the repurposing of drugs on the basis of promising in vitro and therapeutic results with other human coronavirus diseases, such as severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). These repurposed drugs have mainly included remdesivir, favipiravir, lopinavir-ritonavir, ribavirin, interferons, and hydroxychloroquine. Unfortunat
    Document: The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has prompted the repurposing of drugs on the basis of promising in vitro and therapeutic results with other human coronavirus diseases, such as severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). These repurposed drugs have mainly included remdesivir, favipiravir, lopinavir-ritonavir, ribavirin, interferons, and hydroxychloroquine. Unfortunately, the first open-label, randomized, controlled trials are showing poor efficacy of these repurposed drugs. These results highlight the necessity of identifying and characterizing specific and potent SARS-CoV-2 antivirals.

    Search related documents:
    Co phrase search for related documents
    • acute respiratory distress syndrome and load reduction: 1, 2
    • acute respiratory distress syndrome and long period: 1, 2, 3, 4, 5, 6
    • acute respiratory distress syndrome and lopinavir receive: 1
    • acute respiratory distress syndrome and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory distress syndrome and lopinavir ritonavir group: 1
    • acute respiratory distress syndrome and lopinavir ritonavir treatment: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
    • acute respiratory distress syndrome and low efficacy: 1, 2, 3, 4, 5
    • acute respiratory distress syndrome and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory distress syndrome and lung involvement: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory distress syndrome and lung involvement advanced: 1
    • load reduction and long period: 1, 2
    • load reduction and lopinavir ritonavir: 1, 2, 3, 4
    • load reduction and lopinavir ritonavir group: 1
    • long period and low efficacy: 1
    • long period and lung injury: 1
    • long period and lung involvement: 1
    • lopinavir receive and lung involvement: 1
    • lopinavir ritonavir and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • lopinavir ritonavir and lung involvement: 1, 2, 3, 4, 5